55results about "Angiogenesic factors" patented technology

According to the present invention, the siRNA and the polypeptide oligonucleotide drug for inhibiting the expression of the amyloid precursor protein (APP) gene in the human body cell, and the application thereof are provided, the siRNA has good APP expression inhibition activity, and can improve the target silencing ability and reduce the non-target activity through the appropriate modification; the siRNA and the conjugate thereof are expected to be applied to prevention and treatment of diseases such as cerebral amyloid vascular disease (CAA), early onset familial Alzheimer's disease (EOFAD) or Alzheimer's disease (AD) which are related to APP targets clinically.

The present invention relates to the treatment of infectious diseases. In this study, we identify potential defense mechanisms involved in maintaining brain vascular integrity during bacterial infection and perform RNA analysis of primary endothelial cells isolated from human skin (HDMEC) or brain (HBMEC) microvessels. The cells were either uninfected or infected with Neisseria meningitidis in vitro. We found 40 genes, especially ANGPTL4, that are specifically regulated in brain endothelial cells during infection. In the context of sepsis, ANGPTL4 was found to be the main barrier stabilizing protein with a defensive effect against bacterial infection. ANGPTL4 (or derived peptides) also showed potential as an adjunctive therapy to reduce bacteria-induced vascular dysfunction and mortality. Thus, the present invention relates to peptides derived from the protein ANGPTL4 and their use in the treatment of infectious diseases.

Anti-angiopoietin-like protein (ANGPTL) 3 / 8 complex antibodies are provided that can be used to treat diseases and disorders related to lipid metabolism and glucose metabolism. [Solution] Antibodies that bind to the human ANGPTL3 / 8 complex are provided, which include light chain determining regions LCDR1, LCDR2, and LCDR3, and heavy chain determining regions HCDR1, HCDR2, and HCDR3, each having a specific amino acid sequence. Pharmaceutical compositions containing one or more anti-ANGPTL3 / 8 complex antibodies of the invention in a pharmaceutically acceptable carrier are also disclosed. Methods of making and using the above, particularly for increasing lipoprotein lipase activity and lowering triglycerides, are also disclosed.

The invention discloses an application of a substance taking Angpt18 as a target in preparation of a medicine for treating and delaying senescence, and the key regulation effect of an Angpt18 gene in the occurrence and progression process of normal senescence and senescence-related diseases is found for the first time through systematic and in-depth research; further experiments prove that by inhibiting or down-regulating the expression of the Angpt18 gene, the senescence process can be obviously delayed, and the expressions such as hypomnesia and behavioral ability decline in the senescence process can be effectively improved. Therefore, the Angpt18 gene can be used as an important intervention target for senescence and related diseases thereof, can be used for developing drugs with senescence delaying or treatment effects, can also be used as a biomarker for evaluating the senescence degree and diagnosing and prognosing the related diseases of senescence, and has wide application prospects and clinical transformation values.

The present invention provides siRNA, peptide oligonucleotide drugs, and their applications for suppressing the expression of the amyloid precursor protein (APP) gene in human cells. The siRNA exhibits potent activity in inhibiting APP expression. Through appropriate modifications, its ability to silence the target is enhanced while reducing off-target activity. The described siRNA and its conjugates hold promise for clinical application in the prevention and treatment of diseases associated with the APP target, including cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).

Provided herein are compositions comprising an oligonucleotide that targets ANGPTL7. In some embodiments, the oligonucleotide includes modified nucleotides. In some embodiments, the oligonucleotide may be used to reduce intraocular pressure in a subject's eye.

The invention relates to the technical field of feeding of acipenser sibiricum, in particular to an acipenser sibiricum appetite promoting factor angiopoietin-like protein and application thereof, in-vitro prokaryotic recombinant expression of ANGPTL4 mature peptide is achieved for the first time, and acipenser sibiricum ANGPTL4 / pET-32a protein with biological activity is obtained through purification. The provided Acipenser sibiricum ANGPTL4 / pET-32a recombinant protein can lay a foundation for subsequent research on biological functions of ingestion regulation and control.

The present disclosure relates to an siRNA for inhibiting the expression of an angiopoietin-like protein 3 (ANGPTL3) gene, an siRNA conjugate, and a pharmaceutical composition thereof, and a method for reducing the expression of the ANGPTL3 gene by using the siRNA, the siRNA conjugate, and the pharmaceutical composition thereof. The siRNA, the siRNA conjugate, and the pharmaceutical composition thereof of the present disclosure can be used for treating and / or preventing an ANGPTL3 gene-mediated disease or disorder.

A method of inducing lymphangiogenesis in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of inducing lymphangiogenesis in a tumor in the brain or central nervous system of a subject is provided in which an effective amount of a lymphangiogenesis inducer is administered. A method of treating a cancer of the brain or central nervous system is also provided in which an effective amount of a lymphangiogenesis inducer is administered. An example of a lymphangiogenesis inducer is VEGFC. The lymphangiogenesis inducer can be in the form of a protein or a polynucleotide encoding the protein, such as an mRNA or AAV. The lymphangiogenesis inducer can be administered to the cistema magna or directly into the lymphatic system. An immunotherapeutic agent, such as a checkpoint inhibitor, may also be administered.

The present invention provides a novel blood-derived growth-factor-containing composition. The present invention for solving the above problem is a method for preparing a growth-factor-containing composition from blood, the method comprising a step for separating platelet-rich plasma that does not contain a buffy coat component from the blood, and a step for adding citric acid and / or a salt thereof to the blood or a processed product thereof.

The present invention relates to productive tissue repair and regeneration, and in particular poylpeptides, compositions including said polypeptides, and methods of using said polypeptides or compositions for productive tissue repair and regeneration. In one aspect, the invention provides a polypeptide comprising, consisting essentially of or consisting of a C-terminal portion of NAMPT comprising a truncated cytokine finger motif (cif) motif. In another aspect, the present invention provides a fusion protein comprising, consisting essentially of or consisting of a polypeptide of a full length NAMPTcif or truncated variants and a tissue delivery or retention enhancing moiety.

The invention provides a growth factor-dextran conjugate as well as a preparation method and application thereof, the growth factor-dextran conjugate consists of a growth factor and dextran, and is obtained by coupling an amino group of the growth factor and a hydroxyl group of the dextran through a chemical reaction; the growth factor-dextran conjugate can protect the growth factor to enhance the stability of the growth factor, reduce the degradation of the growth factor in vivo and prolong the in vivo half-life period of the growth factor; coupled dextran can be combined with a cell surface receptor to promote cellular uptake of growth factors and enhance the effective action concentration of the growth factors in cells, has good biocompatibility and biological safety, and has wide application in research and development of drugs for wound repair and / or treatment of neurodegenerative diseases.

Compositions and methods are disclosed which comprise a guide polynucleotide corresponding to a protospacer sequence on the Angiopoietin-like protein 3 gene with a view to base editing the Angiopoieti

A composition for editing the PCSK9 gene comprises: (i) an mRNA encoding a protein comprising a programmable DNA binding domain; and (ii) a guide polynucleotide, wherein the guide polynucleotide compr

The present invention relates to the field of nucleic acid editing, in particular the field of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. In particular, the present invention relates to Cas effector proteins, fusion proteins comprising such proteins, and nucleic acid molecules encoding them. The present invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing) comprising the proteins or fusion proteins of the present invention, or nucleic acid molecules encoding them. The present invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using complexes comprising the proteins or fusion proteins of the present invention.

The present invention pertains to the use of gene editing and miRNA technologies for improving recombinant production of ANGPTL3 mimetics in CHO cells. The gene expression modifications are used for knock-out / knock-down of the endogenous protein CCL2 of the CHO cells which is difficult to separate from ANGPTL3 mimetics during purification.

The present invention relates to the treatment of infectious diseases. In this study, we identify potential defense mechanisms involved in maintaining brain vascular integrity during bacterial infection and perform RNA analysis of primary endothelial cells isolated from human skin (HDMEC) or brain (HBMEC) microvessels. The cells were either uninfected or infected with Neisseria meningitidis in vitro. We found 40 genes, especially ANGPTL4, that are specifically regulated in brain endothelial cells during infection. In the context of sepsis, ANGPTL4 was found to be the main barrier stabilizing protein with a defensive effect against bacterial infection. ANGPTL4 (or derived peptides) also showed potential as an adjunctive therapy to reduce bacteria-induced vascular dysfunction and mortality. Thus, the present invention relates to peptides derived from the protein ANGPTL4 and their use in the treatment of infectious diseases.

RNA molecules comprising a guide sequence portion consisting of 17 to 50 nucleotides and containing 17 to 22 nucleotides in the sequence set forth in any one of SEQ ID NO: 1 to 20347, as well as compositions, methods and uses thereof.

Disclosed herein are immunogenic compositions having a circular RNA encoding a VEGF polypeptide. Also provided herein are related methods of manufacture and therapeutic uses thereof.

The invention provides a nucleic acid molecule for treating peripheral artery diseases of lower limbs and encoding multiple angiogenesis factors, a pharmaceutical composition and application of the nucleic acid molecule. Compared with the prior art, the pharmaceutical composition for treating the peripheral artery diseases of the lower limbs, provided by the invention, can remarkably promote angiogenesis of the lower limbs and improve ischemia of the lower limbs.

Disclosed herein are engineered nucleases and nuclease systems, including chimeric nucleases and chimeric nuclease systems. The engineered nucleases and chimeric nucleases disclosed herein include nucleic acid-guided nucleases. Additionally, disclosed herein are methods of producing and using the engineered nucleases.

The object of the present invention is to provide a preventive and / or therapeutic agent for pressure ulcers comprising a conditioned medium of immortalized mesenchymal stem cells to which specific genes are introduced as an active ingredient. The present invention provides the preventive and / or therapeutic agent for pressure ulcers comprising the conditioned medium of immortalized mesenchymal stem cells, to which hTERT or pTERT gene, bmi-1 gene, HPV-E6 gene, and HPV-E7 gene are introduced, as an active ingredient. Here, the mesenchymal stem cells are preferably obtained from either human or swine. The conditioned medium preferably contains at least three or more cytokines selected from the group consisting of insulin-like growth factor binding protein, metalloproteinase tissue inhibitor, vascular endothelial growth factor, hepatocyte growth factor, tumor necrosis factor receptor II, and osteoprotegerin / osteoclast differentiation inhibitory factor; and each in the concentration range thereof is from 1 x 103 to 1 x 106 pg / mL, respectively.

The present disclosure relates to a polypeptide, an RNA molecule and a medical use thereof, and specifically relates to an ANGPTL polypeptide, an RNA molecule, a polynucleotide, a vector, lipid nanoparticles, a pharmaceutical composition and a medical use thereof.

Provided are a nucleic acid molecule encoding a plurality of angiogenesis factors and a pharmaceutical composition for the treatment of peripheral arterial disease in the lower limb, and use thereof. Relative to the prior art, the pharmaceutical composition for the treatment of peripheral arterial disease in the lower limb can significantly promote lower limb angiogenesis and improve lower limb ischemia.

The present invention relates to the treatment of infectious diseases. In this study, the inventors identified the potential protective mechanisms involved in the maintenance of cerebrovascular integrity during bacterial infection, the inventors performed RNA analysis of primary endothelial cells isolated from human dermal (HDMECs) or brain (HBMECs) microvessels, which were left uninfected or were infected in vitro with meningococci. They found 40 genes specifically regulated in cerebral endothelial cells upon infection and notably ANGPTL4. They showed that, in the context of sepsis. ANGPTL4 is a major barrier-stabilizing protein conferring protection against bacterial infection. They also demonstrated the potential of ANGPTL4 (or derived peptide) as adjuvant treatment to reduce bacterial-induced vascular dysfunction and mortality. Thus, the present invention relates to peptide derived from the protein ANGPTL4 and their used in the treatment of infectious diseases.

Methods of determining the severity of an infectious disease, including ruling in sepsis, based on expression level of ANG-2.

RNA molecules comprising a guide sequence portion consisting of 17-50 nucleotides and containing 17-22 nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-20347, and compositions, methods, and uses thereof.